Product Launch (Blog)

May, 02 2024

Leading Players Shaping Gene Synthesis Market: Innovators, Technologies, and Market Dynamics Explained Succinctly

The market continues to witness significant advancement, revolutionizing biotechnology. Enhanced techniques, such as multiplex automated genome engineering, boost synthesis accuracy and efficiency. This progress fosters diverse applications, from pharmaceuticals to agriculture, propelling market growth. Businesses capitalize on tailored gene solutions, fueling demand and innovation. Benefits abound, with tailored genetic constructs offering precise modulation of biological systems for research and commercial endeavors. Improved scalability and cost-effectiveness democratize access to synthetic genes, empowering research across disciplines. As the market expands, collaborations burgeon, fostering cross-disciplinary breakthroughs. Gene synthesis emerges as a cornerstone of biotechnological progress, promising profound impacts on healthcare, sustainability, and beyond.

Data Bridge Market Research analyses that the Global Gene Synthesis Market size was valued at USD 2.65 billion in 2023 and is projected to reach USD 13.79 billion by 2031, with a CAGR of 22.90% during the forecast period of 2024 to 2031.

Below are the Top Five Gene Synthesis Companies with a Significant Market Share:

Rank

Company

Overview

Product Portfolio

Sales Geographical Coverage

Developments

1.

Integrated DNA Technologies, Inc.

 

Renowned for its high-quality custom DNA synthesis services, IDT offers a comprehensive range of synthetic DNA products for various applications, including gene synthesis. With cutting-edge technologies and a focus on customer satisfaction, IDT stands out for its reliability and efficiency in delivering synthesized genes tailored to researchers' needs.

  • MiniGene Synthetic Genes
  • Genes
  • eBlocks Gene Fragments
  • gBlocks Gene Fragments
  • Megamer Fragments

 

Middle East and Africa, America, Europe, Asia-Pacific

 

In August 2022, Integrated DNA Technologies, Inc. (a subsidiary of Danaher) launched Complete NGS Library Preparation Solution for Monkeypox as it will support global efforts across the scientific community—because more discoveries can lead to better prevention and mitigation strategies.

 

2.

Thermo Fisher Scientific Inc.

 

A global leader in scientific solutions, Thermo Fisher Scientific offers advanced gene synthesis services through its extensive portfolio of life science products. Leveraging innovative technologies and expertise, Thermo Fisher provides researchers with customizable gene synthesis solutions to accelerate their discoveries in diverse fields, from biotechnology to medicine.

  • RNA Fragmentation Reagents
  • VetMAX AIV Reagents
  • Lipofectamine LTX Reagent with PLUS Reagent
  • HT 3' IVT PLUS Consumables for Biomek FXP Target Prep Express
  • GenEx Professional Software

 

Middle East and Africa, North America, South America, Europe, Asia-Pacific

 

In August 2022, Thermo Fisher Scientific Inc. announced that they had launched Applied Biosystems HIV-1 Genotyping Kit with Integrase, which will help to examine positive samples of the human immunodeficiency virus (HIV) to identify genetic variants that resist common antiretroviral therapeutics.

 

3.

Eurofins Scientific

 

Eurofins is a prominent player in the gene synthesis market, offering a wide range of genomic services, including custom gene synthesis. With state-of-the-art facilities and a strong emphasis on quality and accuracy, Eurofins caters to the needs of academic and industrial researchers worldwide, providing reliable and cost-effective gene synthesis solutions.

Merck KGaA: As a leading science and technology company, Merck KGaA offers comprehensive gene synthesis services tailored to meet the specific requirements of researchers in the life sciences. With a focus on innovation and collaboration, Merck KGaA delivers high-quality synthetic genes and related products, empowering scientists to advance their research and development initiatives effectively.

  • Standard genes
  • Complex genes
  • Express gene
  • Gene evolution libraries
  • GENEius service

 

Middle East and Africa, Europe, America, and Asia-Pacific

 

In September 2021, Eurofins Scientific Collaborate with Transplant Genomics to launch omnigraf, the only combination biomarker panel that provides the earliest indication of rejection in kidney transplant recipients as it provides significantly higher positive predictive value (ppv) and negative predictive value (npv) than any other kidney rejection assays (or tests) on the market.

 

4.

Merck KGaA

 

As a leading science and technology company, Merck KGaA offers comprehensive gene synthesis services tailored to meet the specific requirements of researchers in the life sciences. With a focus on innovation and collaboration, Merck KGaA delivers high-quality synthetic genes and related products, empowering scientists to advance their research and development initiatives effectively.

  • Novabiochem Peptide and DNA Synthesis Reagents
  • Benzonase
  • CytoBuster
  • YeastBuster
  • BioReliance Cell and Gene Therapy Testing Services

Europe, Africa, Asia, Oceania, America

 

In April 2020, Merck had announced that they will be launching 100 million euros worth of commercial facilities for its BioReliance viral and gene therapy services next year for major advancement in medicine.

 

5.

Kaneka Eurogentec S.A.     

Specializing in biotechnology and pharmaceutical services, Kaneka Eurogentec S.A. provides cutting-edge gene synthesis solutions to support research and development in various industries. With a strong commitment to quality, reliability, and customer satisfaction, Kaneka Eurogentec S.A. offers customizable gene synthesis services and products. This enables researchers to explore and manipulate genetic material with precision and efficiency.

  • Oligos Grades
  • Custom Oligos
  • Probes
  • RNAI
  • Specialized oligos

 

Middle East and Africa, Europe, Asia-Pacific, North America, South America

 

In February 2022, Kaneka Eurogentec announced that its mRNA manufacturing facility had successfully produced a 25 g batch of mRNA for a US customer. This quantity is equivalent to 100,000’s to millions of doses of mRNA, potentially sufficient for late clinical and commercial uses.

 

Conclusion

In conclusion, the market is poised for significant growth driven by escalating demand for personalized medicine, biotechnology advancements, and expanding applications in various sectors. The convergence of these factors presents a compelling opportunity for market players to innovate and capitalize on emerging trends. With continued technological advancements and increasing investment in research and development, the gene synthesis market is positioned to thrive, ushering in a new era of transformative solutions.


Client Testimonials